Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Supernus Pharm (SUPN)

Supernus Pharm (SUPN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Supernus Pharm 9715 Key West Avenue ROCKVILLE MD 20850 USA

www.supernus.com Employees: 652 P: 301-838-2500

Description:

Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.

Key Statistics

Overview:

Market Capitalization, $K 2,000,032
Enterprise Value, $K 1,924,982
Shares Outstanding, K 55,219
Annual Sales, $ 607,520 K
Annual Net Income, $ 1,320 K
Last Quarter Sales, $ 175,690 K
Last Quarter Net Income, $ 38,500 K
EBIT, $ 140,060 K
EBITDA, $ 225,330 K
60-Month Beta 0.86
% of Insider Shareholders 9.30%
Float, K 50,084
% Float 90.70%
Short Volume Ratio 0.60

Growth:

1-Year Return 32.14%
3-Year Return 18.33%
5-Year Return 54.92%
5-Year Revenue Growth 48.57%
5-Year Earnings Growth -99.02%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 1.06 on 11/04/24
Next Earnings Date N/A
Earnings Per Share ttm 1.33
EPS Growth vs. Prev Qtr 163.89%
EPS Growth vs. Prev Year 427.59%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

SUPN Ratios

Ratio
Price/Earnings ttm 26.93
Price/Earnings forward 15.14
Price/Earnings to Growth N/A
Return-on-Equity % 7.79%
Return-on-Assets % 5.67%
Profit Margin % 0.22%
Debt/Equity 0.00
Price/Sales 3.26
Price/Cash Flow 22.60
Price/Book 1.96
Book Value/Share 18.24
Interest Coverage 2.14
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar